HCW Biologics Inc. is a preclinical stage biopharmaceutical company. It focused on discovering and developing novel immunotherapies. HCW Biologics Inc. is based in MIRAMAR, Fla.
| Revenue (Most Recent Fiscal Year) | $0.05M |
| Net Income (Most Recent Fiscal Year) | $-7.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.66 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.90 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -29.73% |
| Net Margin (Trailing 12 Months) | -34.73% |
| Return on Equity (Trailing 12 Months) | -486.87% |
| Return on Assets (Trailing 12 Months) | -29.19% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.84 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-9.46 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 6.73M |
| Free Float | 6.12M |
| Market Capitalization | $10.98M |
| Average Volume (Last 20 Days) | 36.71M |
| Beta (Past 60 Months) | 2.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 2.96% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |